OPINION EDITORIAL ON HERITAGE CREATIVE BEATS INTERALIA WIDE ANGLE OTHER VIEW ART SPACE

A Cardio-Renal-Metabolic Paradigm Shift

Recent Advances in the Pharmacological Management of Diabetes Mellitus:

Representational Photo

Diabetes mellitus has emerged as one of the most pressing global health challenges of the 21st century, with an estimated 643 million adults projected to be affected by 2030. The disease accounts for millions of deaths annually and imposes a substantial economic burden due to its chronic complications. Contemporary diabetes management has undergone a remarkable transformation, shifting from a purely glucose-centric model to a comprehensive cardio-renal-metabolic (CRM) approach. This paradigm shift emphasizes not only glycaemic control but also the prevention of cardiovascular and renal complications, alongside weight management and individualized care.

At the core of this evolution lies an enhanced understanding of diabetes pathophysiology. Traditional concepts focused primarily on insulin resistance and beta-cell dysfunction; however, modern frameworks such as the “ominous octet” and the expanded “egregious eleven” highlight additional mechanisms, including incretin deficiency, renal glucose reabsorption, alpha-cell dysregulation, and systemic inflammation. This broader understanding has paved the way for targeted pharmacological interventions that address multiple metabolic pathways simultaneously.

Tribal Sports Talent: Our National Pride

The Wealth Game Schools Never Taught Us

Closing of the Financial Year: Strengthening Accountability and Ensuring Smooth Public Services

Metformin continues to serve as the foundational therapy for type 2 diabetes mellitus (T2DM), owing to its efficacy, safety, affordability, and weight-neutral profile. Beyond glycaemic control, emerging evidence suggests potential pleiotropic benefits, including anti-aging effects mediated through AMP-activated protein kinase (AMPK) activation and possible reductions in cancer risk. Nonetheless, long-term therapy necessitates monitoring for vitamin B12 deficiency. While sulfonylureas remain effective in lowering HbA1c, their declining use reflects concerns regarding hypoglycemia and weight gain. Thiazolidinediones, particularly pioglitazone, have found a niche role in insulin resistance and metabolic-associated steatohepatitis (MASH), though their use is limited by adverse effects.

One of the most transformative developments in diabetes pharmacotherapy is the incretin revolution. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated robust efficacy in glycaemic reduction, weight loss, and cardiovascular risk mitigation. Agents such as liraglutide, dulaglutide, and........

© Kashmir Images